Phase I only - Dose-limiting toxicities After 2 cycles of chemotherapy. (6 weeks after start of treatment) [clinicaltrials_resource:f4c58c7f27fec0bcc14c5a0a0b6ad35c]
Calculated as the time between the date of randomisation and date of first progression or death (from any cause), whichever occurs first. Patients who have not died or progressed will be censored at the date last seen alive (ie. the last assessment).
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Phase I only - Dose-limiting toxicities After 2 cycles of chemotherapy. (6 weeks after start of treatment) [clinicaltrials_resource:f4c58c7f27fec0bcc14c5a0a0b6ad35c]
Calculated as the time between the date of randomisation and date of first progression or death (from any cause), whichever occurs first. Patients who have not died or progressed will be censored at the date last seen alive (ie. the last assessment).
Bio2RDF identifier
f4c58c7f27fec0bcc14c5a0a0b6ad35c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:f4c58c7f27fec0bcc14c5a0a0b6ad35c
measure [clinicaltrials_vocabulary:measure]
Phase I only - Dose-limiting toxicities
time frame [clinicaltrials_vocabulary:time-frame]
After 2 cycles of chemotherapy. (6 weeks after start of treatment)
description
Calculated as the time between ...... ive (ie. the last assessment).
identifier
clinicaltrials_resource:f4c58c7f27fec0bcc14c5a0a0b6ad35c
title
Phase I only - Dose-limiting t ...... eeks after start of treatment)
@en
type
label
Phase I only - Dose-limiting t ...... 58c7f27fec0bcc14c5a0a0b6ad35c]
@en